Confronto
Lixisenatide vs. Pemvidutide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
320367-13-3
nessun dato
Peso molecolare
4858.5 g/mol
nessun dato
Emivita
3 h
nessun dato
Sequenza
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2nessun dato
Meccanismo d'azione
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Pemvidutide
The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
5
1
di cui sull'uomo
5
1
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Lixisenatide and Pemvidutide?
- Lixisenatide is classified as "Metabolico", while Pemvidutide is classified as "Metabolico". Lixisenatide: Synthetic exendin-4 analog with a C-terminal lysine extension. Prandial GLP-1 RA focused on postprandial glucose. FDA-approved 2016 as Adlyxin; EMA-approved 2013 as Lyxumia. Sanofi discontinued US distribution in 2023. Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lixisenatide or Pemvidutide?
- The highest available evidence level is "RCT sull'uomo" for Lixisenatide and "Studio sull'uomo" for Pemvidutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lixisenatide and Pemvidutide in Germany and the United States?
- Germania: Lixisenatide — Su prescrizione, Pemvidutide — Non approvato. Stati Uniti: Lixisenatide — Non approvato, Pemvidutide — Non approvato. These are factual summaries with source and review date on the individual pages.